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ABSTRACT
Treatment of gestational trophoblastic diseases (GTD) involves surgery, 
radiotherapy and chemotherapy. Although, these therapeutic approaches are highly 
successful, drug resistance and toxicity remain a concern for high risk patients. This 
Chemoresistance has also been observed in the presence of cancer stem cells that are 
thought to be responsible for cases of cancer recurrence. In this study, we report the 
presence of previously unknown populations of trophoblastic stem-like cells (SLCs) 
that are resistant to the chemotherapeutic drug doxorubicin. We demonstrate that 
these populations express the stem cell markers NANOG and Sox2 and higher levels 
of OCT-4 (NANOG+/OCT-4high/SOX2+). Although chemoresistant, we show that the 
invasive capacity of these trophoblastic SLCs is significantly inhibited by doxorubicin 
treatment. To better characterise these populations, we also identified cellular 
pathways that are involved in SLCs-chemoresistance to doxorubicin. In summary, 
we provide evidence of the presence of NANOG+/OCT-4+/SOX2+ trophoblastic SLCs 
that are capable to contribute to the susceptibility to GTD and that may be involved 
in Chemoresistance associated with drug resistance and recurrence in high risk 
GTDs’ patients. We propose that targeting these populations could be therapeutically 
exploited for clinical benefit.
INTRODUCTION
Gestational trophoblastic diseases (GTD) are group 
of rare conditions that are associated with abnormal 
growth of trophoblast cells in the uterus. They can be 
caused by hydatiform moles and choriocarcinoma. 
Healthy trophoblastic cells are highly invasive toward 
the endometrium and are essential to the development of 
a rich uterine vasculature that is necessary for placenta 
formation [1–3]. However, in gestational trophoblastic 
disease the regulatory mechanisms fail, which result in 
tumours that are highly invasive, metastatic, and vascular 
[4]. Treatment of GTD involves surgery, radiotherapy 
and chemotherapy which can achieve 84-100% success 
depending on risk factors [5]. Unfortunately, some women 
die from the disease due to chemotherapy-associated 
toxicity and drug resistance [6]. Therefore, understanding 
the reasons associated with these limitations would 
improve the efficacy and help reduce drugs toxicity.
Chemotherapy is based on the ability of a drug 
to halt or destroy rapidly dividing cells. However, their 
efficacy is limited by two main issues: (i) their inability 
to differentiate between normal and highly dividing cells” 
such as hair follicles, intestinal epithelial and gonadal 
cells, and neoplastic cells [7]; (ii) the emergence of a 
self-renewing cell pool called “cancer stem cells” (CSC) 
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within the tumour [8, 9]. The former is responsible for 
the unwanted side effects and the latter results in drug 
resistant tumours. Interestingly, in GTD, trophoblast 
cells of the human placenta can have similar behaviour to 
cancer stem cell-like cells [10] as they also demonstrate 
the ability to produce stem-like cells during first trimester 
invasion [11]. In fact, several similarities can be observed 
between tumour and trophoblast development [12, 
13]. They both have a very high capacity to proliferate, 
differentiate, and invade surrounding tissues to establish 
a blood and nutrient supply by degrading the extra-
cellular matrix (ECM) including changes in cell adhesion 
molecules, secretion of proteases, and growth factors [14, 
15]. They also share other characteristics such immune 
response evasion, survival [12] and increased angiogenesis 
[16]. Based on this background, we hypothesised that 
transformed trophoblast cells contain populations of 
stem cell/cancer stem like cells that are resistant to 
chemotherapeutic agents. Furthermore, we reveal the 
existence of a population of trophoblast stem-like cells 
(SLCs) that express the stem cells markers OCT-4, SOX2, 
and NANOG and trophoblast transcription factor (CDX2) 
that are capable of self-renewal by generating spheroids.
We also investigated the effect of doxorubicin on 
these cells and we showed that within NANOG+/OCT-4+/_/
SOX2+trophoblast SLCs only NANOG+/OCT-4high/SOX2+ 
populations are resistant to doxorubicin. We also show that 
the invasive capacity of these populations is significantly 
inhibited by doxorubicin treatment. Moreover, we investigated 
by proteomic analysis cellular pathways that are involved in 
trophoblast SLCs resistance to doxorubicin. Collectively, 
these studies demonstrate the existence of trophoblast SLCs 
that are chemoresistance and that may explain drug resistance 
observed in some cases of Gestational trophoblastic diseases.
RESULTS
Identification of stem-like cells (SLCs) from 
transformed trophoblastic cell lines
As limited attempts have been made to identify 
SLCs from trophoblastic cells, we set out to investigate 
their presence in transformed first trimester trophoblastic 
cell lines (HTR8/SVneo and TEV-1). For this purpose, we 
used sphere formation assay that aims at testing the capacity 
of these cells to self-renew, a property associated with 
stemness. We observed that transformed trophoblastic cell 
lines are able to generate spheres (Figure 1A). These cells 
are also able to generate spheres following treatment with the 
chemotherapeutic drug doxorubicin (Figure 1B). For further 
characterisation, we investigated the expression of specific 
stem cell markers such as OCT-4, NANOG and SOX2 in 
parental and spheroid cells by immunofluorescence staining 
and using specific antibodies. Spheroids that were generated 
from trophoblastic cells showed positive staining for OCT-4, 
SOX2 and NANOG (Figure 2A and 2B). Although, HTR8/
SVneo parental cells also expressed SOX2, NANOG and 
OCT-4, the expression of OCT-4 was not observed in TEV-
1 parental cells (Figure 2A). These results demonstrate that 
trophoblastic cell lines can generate stem-like cells that 
are able to self-renew and express the stem cell markers 
OCT-4, NANOG and SOX2. These were confirmed both 
by QRTPCR (mRNA) and immunoblotting (protein) 
(Supplementary Figure 1A - 1D).
Transformed trophoblastic stem-like cells (SLCs) 
are resistant to doxorubicin treatment
To investigate the effect of doxorubicin on 
trophoblastic stem-like cells, we treated transformed 
trophoblastic cells (parental) as well as spheroids that 
were originated from these cells with doxorubicin and we 
performed an immunofluorescence staining with OCT-4, 
NANOG and SOX2 antibodies. The expression of these 
markers was observed in both HTR8/SVneo and TEV-1 
treated spheres. HTR8/SVneo parental cells expressed 
NANOG, SOX2 and OCT-4 (Figure 2A and 2B); however 
treated TEV-1 parental cells expressed only SOX2 and 
NANOG. Whole cell lysates from untreated and treated 
spheroids and parental cells were used for immunobloting 
with specific antibodies against OCT-4, NANOG and 
SOX2. Although we observed that the expression of 
OCT-4, NANOG and SOX2 was significantly increased 
in spheroids that were originated from trophoblastic cells, 
no increase of OCT-4 expression was noticed in TEV-1 
trophoblastic cells (Figure 3). Conversely, an increase of 
OCT-4 expression was observed in doxorubicin-treated 
spheroids that were originated from TEV-1 (Figure 
3A). This may be explained by the presence of OCT-
4 SLCs a small subpopulation within TEV-1 SLCs that 
expresses NANOG and SOX2, and that are resistant to 
doxorubicin. Moreover, no significant difference was 
observed in NANOG and SOX2 expression between 
untreated and treated trophoblastic cells (Figure 3B and 
3C). Although, OCT-4 expression was affected in treated-
parental TEV-1, a decrease of OCT-4 expression was also 
observed in doxorubicin treated HTR8/SVneo (Figure 
3A). Finally, there were no significant changes observed 
in protein expression of the trophoblastic marker CDX2 
in HTR8/SVneo and TEV-1 cell lines. However, CDX2 
expression was increased in doxorubicin-treated HTR8/
SVneo spheroids compared to untreated spheroids (Figure 
3D). These results demonstrate that NANOG+/OCT-4high/
SOX2+ SLCs populations from trophoblastic cells are 
resistant to the chemotherapeutic effect of doxorubicin.
Doxorubicin treatment inhibits invasion of 
spheres from transformed trophoblastic cell lines
To determine the effect of doxorubicin on the 
invasive capacity of spheres originated from transformed 
trophoblast cell lines, we used the BD BioCoat tumour 
invasion plates. This assay allows the study of the 
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Figure 1: Generation of non-resistant and doxorubicin-resistant spheroids from transformed trophoblast cell lines. The 
ability of trophoblast cells (HTR8/SVneo and TEV-1) to generate non-resistant spheroids are shown in Panels (A). Row 1 = Parental cells 
without treatment; Row 2 = Spheroidal cells produced from non-adherent 3-D culture; Row 3 = the ability of spheroidal cells to re-grow 
onto normal adherent 2-D culture. Likewise, trophoblast cells (HTR8/SVneo, TEV-1) have the ability to generate doxorubicin-resistant 
spheroids shown in Panel (B). Row 1 = Parental cells without treatment; Row 2=Parental cells treated with 250ng/ml of doxorubicin. 
Row3 = Spheroidal cells produced from non-adherent 3-D culture; Row 3 = the ability of spheroidal cells treated to re-grow onto normal 
adherent 2-D culture. Scale bar= 100μm.
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Figure 2: Expression of NANOG, OCT-4 and SOX2 in transformed trophoblast spheroids and parental cells. (A) (B) 
Immunofluorescence micrographs of OCT-4, SOX2 and NANOG with DAPI staining in HTR8/Svneo and TEV-1 transformed parental 
trophoblast cell lines. (B) Immunofluorescence micrographs OCT-4, SOX2 and NANOG with DAPI staining in transformed trophoblast 
spheroids. Objective magnification 40X. Scale bar = 50μm.
Figure 3: OCT-4, SOX2 and NANOG expression in untreated and treated transformed parental trophoblast cells and 
spheroids. (A) (B) (C) (D) Immunoblots showing the expression of OCT-4, SOX2, NANOG, CDX2 and corresponding β-actin loading 
controls in HTR8/SVneo and TEV-1 untreated and treated transformed parental trophoblast cells and spheroids.
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invading capacity of cells by comparing the number of 
cells invaded under different conditions. Prior to the 
invasion assay, the spheroids were dissociated into single 
cells using trypsin (Figure 4A). Doxorubicin-treated 
spheroids from the trophoblastic cells HTR8/SVneo 
and TEV-1 cells showed decreased invasive capacities 
when compared to untreated spheroids (Figure 4B and 
4C). To further confirm these results, we used another 
cell invasion assay, the 3-D Spheroid BME cell invasion 
assays, to compare the invasive potential of untreated and 
Figure 4: Comparative cell invasion of untreated and treated transformed trophoblast SLCs. (A) Schematic representation 
of invasion assay. (B) (C) represent the number of HTR8/SVneo and TEV-1 cells invaded at 24 h. A t tests was carried out. Data represent 
the mean ±SD of three individual experiments, each performed in triplicate (****p<0.0001; *p<0.05). Objective magnification 20X (Scale 
bar = 100 μm).
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doxorubicin-treated spheroidal cells. Image J software was 
used to analyse all confocal microscopy images and to 
measure changes in the invasion area at 12, 24 and 48 hrs. 
We observed a significant decrease of invasion of HTR8/
SVneo doxorubicin-treated spheroids when compared to 
their untreated counterpart (Figure 5A). This decrease 
correlated with time. At 12 hrs, there was no significant 
difference in the invasion capacity between untreated and 
doxorubicin-treated spheroids. However, a significant 
increase was observed with untreated spheroidal cells at 
24 and 48 hrs. This pattern of invasion was also noticed 
with TEV-1 untreated and treated spheroids (Figure 5B). 
These results demonstrate that the invasive property of the 
trophoblastic SLCs is inhibited by doxorubicin.
Proteomic analyses of cellular pathways involved 
in trophoblastic SLCs response to doxorubicin 
treatment
To investigate potential cellular pathways that are 
involved in trophoblastic SLCs response to doxorubicin 
treatment, we performed proteomic analyses of untreated 
and treated HTR8/SVneo and TEV-1 spheroids. Proteins 
with significant differential expression were selected 
for further analysis using Metacore software (Thomson 
Reuters, Tables 1 and 2). In the HTR8/SVneo model, we 
identified several cellular pathways that were activated. 
These pathways are involved in cytoskeleton remodelling, 
cell adhesion and migration, cell cycle initiation, apoptosis 
and survival, and immune response (Supplementary 
Table 1). Among the highly expressed proteins MyHC 
(Myosin Heavy Chain) was found to be associated with 
most of these pathways and this suggests a potential 
key role in trophoblastic SLCs response to doxorubicin. 
Conversely, pathways that are involved in glycolysis and 
gluconeogenesis, spindle assembly and transport were 
negatively regulated (Supplementary Table 2). In the 
TEV-1 model, we identified 1 main activated pathway 
that is associated with cytoskeleton remodelling mediated 
by PKA (Protein Kinase A) (Supplementary Table 3). 
The LIM and SH3 domain protein 1 (LASP1) appears 
to play a key role in this process. This was confirmed 
by immunoblotting (Supplementary Figure 2). On the 
other hand, several cellular pathways are downregulated 
and are involved in immune response mediated by the 
Major Histocompatibility Class I (MHC class I), ubiquitin 
pathway, CFTR folding and maturation pathway, and 
apoptosis and survival (Supplementary Table 4). The 
dowregulation of these pathways appears to be due to 
decreased expression of Calreticulin, PDIA3 (Protein 
Disulfide Isomerase Family A Member 3), HSP70 
(Heat Shock Protein Family A) and GRP78 (Glucose-
Regulated Protein, 78kDa). Although, treated HTR8/
SVneo and TEV-1 spheroids appear to respond differently 
Figure 5: 3-D Invasion of untreated and doxorubicin-treated spheroids. (A) (B) Invasion pattern of untreated and treated 
HTR8/Svneo and TEV-1 spheroids and corresponding quantitative analysis of invasion areas. A two-way ANOVA followed by Sidak’s 
for multiple comparisons was carried out. Data represent the mean ±SD of three individual experiments, each performed in quintuplicate 
(****p<0.0001; ***p<0.001; **p<0.01). Objective magnification=10X.
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Table 1: Protein expression changes following treatment in HTR8/SVneo spheroids. Quantitation is by SWATH-MS 
and data analysis in the SCIEX OneOmics cloud processing platform (n=4 biological replicates, OneOmics confidence 
over 60%.
Protein Absolute Fold 
Change
OneOmics 
Confidence %
Up in HTR Spheres 
Treated
RPN1_HUMAN
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1
5.28 68.3
CALX_HUMAN Calnexin 4.40 70.9
BASI_HUMAN Basigin 3.55 70.7
STOM_HUMAN Erythrocyte band 7 integral membrane protein 2.78 80.6
VTNC_HUMAN Vitronectin 2.35 72.6
COX5A_HUMAN Cytochrome c oxidase subunit 5A, mitochondrial 2.27 61.7
PHB_HUMAN Prohibitin 1.68 80.4
NASP_HUMAN Nuclear autoantigenic sperm protein 1.68 65.5
NHRF1_HUMAN
Na(+)/H(+) exchange 
regulatory cofactor NHE-
RF1
1.63 73.7
LMNB2_HUMAN Lamin-B2 1.53 60.5
MYH9_HUMAN Myosin-9 1.51 85.7
PHB2_HUMAN Prohibitin-2 1.51 65.7
CLCA_HUMAN Clathrin light chain A 1.48 65.6
K2C8_HUMAN Keratin, type II cytoskeletal 8 1.46 66.0
GLU2B_HUMAN Glucosidase 2 subunit beta 1.44 79.3
Down in HTR Spheres 
Treated
RAN_HUMAN GTP-binding nuclear protein Ran -1.19 64.9
RLA0_HUMAN 60S acidic ribosomal protein P0 -1.46 61.1
PGK1_HUMAN Phosphoglycerate kinase 1 -1.47 84.2
ENOG_HUMAN Gamma-enolase -1.48 79.7
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase -1.55 63.2
1433T_HUMAN 14-3-3 protein theta -1.60 68.7
G6PI_HUMAN Glucose-6-phosphate isomerase -1.63 69.6
PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B -1.65 70.2
ACADV_HUMAN
Very long-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial
-1.69 69.9
GNPI1_HUMAN Glucosamine-6-phosphate isomerase 1 -1.81 72.8
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to doxorubicin treatment, the cytoskeleton remodelling 
pathway appears to be one of the key upregulated cellular 
process as it is found upregulated in both HTR8/SVneo 
and TEV-1 spheroid models.
DISCUSSION
Chemotherapy is based on the ability of a drug to halt 
or destroy rapidly dividing cells. However, their efficacy 
is limited by (i) their inability to differentiate between 
normal and highly dividing cells [6]; (ii) the emergence of 
a self-renewing cell pool called “cancer stem cells” (CSC) 
within the tumour [7, 17, 18]. In GTDs, similar concerns 
are associated with chemotherapy-associated toxicity and 
drug resistance in high risk patients. These therapeutic 
limitations may also be due to the existence of tumorigenic 
trophoblastic SLCs that confers resistance to chemotherapy. 
Therefore, identifying and characterising these populations 
is essential to help improve the efficacy of chemotherapy 
for patients at high risk of GTDs. Historically, two different 
types of trophoblast cells have been used as in vitro models 
(a) transformed first trimester trophoblast cell lines [19–
21]; and (b) choriocarcinoma which were originated from 
trophoblast tumours [22–24]. As we aimed to understand 
whether the early trophoblast cells (per se) are capable of 
producing SLC’s contributing to the susceptibility of GTD, 
the cell lines derived from choriocarcinoma (such as Jar, 
JEG-3, or BeWo) are not suitable for this study. In contrast 
the cell lines HTR8/SVneo and TEV-1 were transformed 
using viral vectors and proved to show the physiological 
behaviours of early first trimester trophoblast cells [19–21].
In this study, we have identified populations 
of NANOG+/OCT-4+/_/SOX2+ trophoblastic SLCs 
that are able to self-renew and to generate spheroids. 
Interestingly, only populations that are NANOG+/OCT-
4high/SOX2+ are resistant to doxorubicin treatment. This 
finding pinpoints to the fact that only a subpopulation of 
transformed trophoblastic SLCs (NANOG+/OCT-4high/
SOX2+) resist to doxorubicin treatment and implies that 
this subpopulation might be responsible for at least cases 
of GTDs’ chemoresistance.
Cancer stem cells are also associated with invasion 
and metastasis following chemotherapy [25–29]. In 
this regard, we have investigated the invasion capacity 
of identified chemoresistant trophoblastic SLCs and 
in response to doxorubicin. Although, the invasion 
of transformed trophoblastic SLCs was significantly 
decreased, these results suggest that following 
Table 2: Protein expression changes following treatment in TEV-1 spheroids. Quantitation is by SWATH-MS and data 
analysis in the SCIEX OneOmics cloud processing platform (n=4 biological replicates, OneOmics.
Protein Absolute Fold Change OneOmics Confidence 
%
Up
COTL1_HUMAN Coactosin-like protein 2.123830573 0.669641101
RL21_HUMAN 60S ribosomal protein L21 1.918845638 0.636431099
EF1G_HUMAN Elongation factor 1-gamma 1.607650899 0.739079333
LASP1_HUMAN LIM and SH3 domain protein 1 1.512337143 0.605927912
RSSA_HUMAN 40S ribosomal protein SA 1.453157634 0.676316894
Down
TPIS_HUMAN Triosephosphate isomerase -1.499305054 0.608419546
PDIA3_HUMAN Protein disulfide-isomerase A3 -1.781548127 0.746982791
ML12A_HUMAN Myosin regulatory light chain 12A -1.992053636 0.684952806
PDIA1_HUMAN Protein disulfide-isomerase -2.023966219 0.701529248
GRP78_HUMAN 78 kDa glucose-regulated protein -2.756855044 0.898932262
CALR_HUMAN Calreticulin -2.993779141 0.62324947
VTNC_HUMAN Vitronectin -3.815950175 0.671235282
Oncotarget9www.impactjournals.com/oncotarget
chemotherapy, these populations of SLCs may re-initiate 
the invasive process that could lead to more aggressive 
forms of GTDs. In fact, Gestational trophoblastic disease 
(GTD) comprises a spectrum of disorders from the pre-
malignant conditions of complete and partial hydatidiform 
moles to the malignant invasive mole (choriocarcinoma) 
and in very rare cased placental site trophoblastic tumour/
epithelioid trophoblastic tumour (PSTT/ETT) [29]. 
These populations may contribute to these transitions by 
adopting aggressive phenotypes that are associated with 
cancer stem cells.
Furthermore, proteomic analyses of transformed 
trophoblastic SLCs led to the identification of several 
cellular pathways that may play an important role in 
their response to doxorubicin. Cytoskeleton remodelling 
pathways were identified as highly upregulated in treated 
SLCs spheroids. These pathways are involved in cell 
adhesion, migration and invasion. Although this is not 
surprising, the results confirm our observations with 
regard to SLCs capacity to generate spheroids which 
involves cell-cell adhesions and the anti-invasive effect in 
response to doxorubicin. Other cellular pathways such as 
spindle assembly and glucose metabolism were negatively 
regulated. Spindle assembly is an important step in cell 
division and the downregulation of this pathway could 
be explained by the known effect of doxorubicin on the 
cell cycle of dividing cells. Increased glucose metabolism 
has been associated with embryonic stem cells and is 
considered as one of the hallmarks of cancer stem cell 
metabolism [30, 31]. The downregulation of this pathway 
could be explained by the elimination of non-resistant 
trophoblastic SLCs (NANOG+/OCT-4+/_/SOX2+) or 
the slow-down of glucose metabolism in doxorubicin-
resistant SLCs (NANOG+/OCT-4high/SOX2+). Finally, 
increased levels of expression of OCT-4 correlated with 
chemoresistance in several cancers [32], which suggests 
potential involvement of OCT-4 in the chemoresistance 
that is observed in our study. Taken together, these 
observations highlight the presence in transformed 
trophoblast of a population of SLCs (NANOG+/OCT-4high/
SOX2+) that are resistant to doxorubicin treatment and 
provide further insights on the role of trophoblastic SLCs 
in GTDs associated-chemoresistance.
MATERIALS AND METHODS
Antibodies
For this study, we used anti-OCT4 (1:200 for IF, 
1:500 for WB, ab18976 Abcam), anti- SOX2 (1:500 for IF, 
1:1000 for WB, ab97959 Abcam), anti-NANOG (1:50 for 
IF, 1:500 for WB, OAAB11202, Aviva Systems Biology), 
anti-CDX2 (1:100 for IF, ab15258 Abcam; 1:500 for WB, 
ab88129 Abcam), anti-beta actin (1:1000 for WB, ab8227 
Abcam) and Anti-LASP1 (1:1000 for WB, ab156872 
Abcam).
Cell lines and growth conditions
Two cell lines were used in this study. Two include 
HTR8/SVneo (kindly provided by Dr Charles Graham, 
University of Kingston, Canada) and TEV-1 (obtained 
from Dr Mei Choi Choey, University of Hong Kong, 
China). These cell lines were cultured in RPMI-1640 
medium. The media were supplemented with 10% (v/v) 
FBS (foetal bovine serum) (Lonza), 1% (w/v) L-glutamine 
(Lonza) and 1% (v/v) penicillin/streptomycin (Lonza). 
Cells were grown in T25 flasks, incubated at 37°C in 5% 
(v/v) CO2 under humid conditions.
Generation of non-resistant and drug-resistant 
(Doxorubicin) spheroids
The Spheroids were produced under two different 
conditions for the production of non-resistant spheroids 
cells were grown under normal cell culture conditions for 
72 hrs. After 72 hrs, cells were trypsinised and 5 x 106 cells 
were seeded in an ultra-low attachment (non-adherent) T75 
flask in 20 mL of serum-free media. This media contained 
(1% w/v L-glutamine and 1% v/v penicillin/streptomycin) 
supplemented with growth factors, insulin and 0.4% BSA. 
The spheroid generation was monitored and they were 
separated from the single cells by subjecting them to 
gravity separation. Later these spheroids were harvested by 
centrifugation and allowed to grow for 72 hrs. The same 
methodology was followed for producing drug resistant 
spheroids except for the treatment of cells with 250 ng/
mL of doxorubicin before performing aforementioned 
steps. The expression of various markers was later 
studied in both non-resistant and resistant spheroids using 
immunofluorescence, QRTPCR and immunoblotting.
Immunofluorescence staining
Spheroids were collected from the non-adherent 
flask and transferred into 15 mL universal tubes by 
centrifuging at 500 x g for 10 mins, and then washed 
with PBS. The collected spheroids were fixed in 4% 
formaldehyde for 30 min at room temperature and washed 
three times with PBS. Nonspecific reactivity was blocked 
by incubating the cells in blocking solution (1% BSA 
in PBS Tween20) for 1 h. Subsequently the cells were 
subjected to primary antibody treatment for overnight at 
4°C followed by the treatment with secondary antibody. 
After washing with PBS, cells were then transferred onto 
slides and mounted with two drops of VECTASHIELD® 
HardSet™ mounting medium and the boundaries were 
secured by means of a hydrophobic image barrier pen 
(Vector Laboratories, Inc). Spheroid images were captured 
under fluorescent microscope using an Olympus camera. 
Parental adherent cells were grown onto sterile glass cover 
slips GG-18-PLL (neuVitro), poly-l-lysine coated cover-
slips under the respective growth conditions and was used 
as control.
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RNA extractions and quantitative real-time PCR 
(qRT-PCR)
QRT-PCR was carried out to determine the mRNA 
expression level. RNeasy® Plus Mini-kit (Qiagen, Inc) was 
used to extract the total of RNA from cell lines according 
to manufacturer’s instructions. The RNA integrity and 
purification was determined by denaturing 1.5% agarose gel 
electrophoresis. The purity and concentration of RNA was 
determined by using Nanodrop 2000 spectrophotometer 
(Thermo Scientific) at a wavelength of 260 nm. 
Complementary DNA (cDNA) was then synthesized from 
RNA extracted using SuperScript™ II Reverse Transcriptase 
kit (Invitrogen®) according to manufacturer’s instructions. 
The primers were designed using the Primer 3® Input version 
4 software. Details of primers (supplied by MWG Eurofin, 
Germany). The sequences of forward and reverse primers 
were: OCT-4 (NCBI accession no. NM_001285986.1; 
5’ AATTTGTTCCTGCAGTGCCC 3’ and 5’ 
CTCTCGTTGTGCATAGTCGC 3’), SOX2 (NCBI accession 
no. NM_003106.3; 5’ CGGAAAACCAAGACGCTCAT 
3’ and 5’TTCATGTGCGCGTAACTGTC 3’), 
NANOG (NCBI accession no. NM_001297698.1; 
5’CCATCCTGCAAATGTCTTCTG 3’ and 
5’ CTTTGGGACTGGTGGAAGAAT 3’), 
CDX2 (NCBI accession no. NM_001265.4; 
5’ GGGAGGACTGGAATGGCTAC 3’ and 5’ 
CCCAGAAGCGCAGGAAGG 3’). The qRT-PCR was 
performed using Rotor-Gene 6000 real time PCR cycler 
(Qiagen). The mRNA was normalised against averaged 
expression of the house-keeping genes [hypoxanthine 
phosphoribosyltransferase-1 (HPRT1) and TATA Box 
Binding Protein (TBP1)] in the same samples and 2-ΔΔCt 
was calculated.
Immunoblotting
Harvested cells (both parental and spheroidal) were 
lysed directly in lysis buffer to collect whole cell extracts. 
Cells were washed twice with PBS then transferred into 
20 mL universal tubes and centrifuged at 27,000 x g for 
15 mins at 4°C. The supernatant was discarded and the 
pellet was washed with PBS. To the cells, 300 μL RIPA 
buffer with 0.2 mL protease inhibitor cocktail (Roche) 
0.2% (v/v) and 1mM Na3VO4 (Sigma Aldrich) were 
added and the resulting cell lysate was boiled for 5 min 
at 95°C followed by storing the lysate -20°C and used 
whenever needed. Protein samples (30 μg) were separated 
using (SDS/PAGE; 10% (w/v) polyacrylamide gel) using 
a Bio-Rad Mini-Protean III system which were then 
transferred to nitrocellulose membranes using a Bio-Rad 
Trans-Blot system for 1 h at 100 volts in (25 mM Tris, 
192 mM glycine, and 20% MeOH). Following transfer, the 
membranes were washed with PBS and blocked for 1 h at 
room temperature in blocking buffer (3% w/v BSA in 1X 
TBS-Tween20). The membranes were incubated overnight 
at 4°C with respective primary antibodies and incubated 
with the respective secondary antibody for 1-2 h. The ultra 
chemiluminescence detection system (Cheshire Sciences 
Ltd) was used to visualize the bands, and they were 
quantified by densitometry using Advanced Image Data 
Analysis Software (Fuji; version 3.52). The expression 
levels of the proteins of interest were normalised against 
the house keeping protein β-actin.
Invasion assay
To compare the invasion/migration capacities 
of spheroidal cells with their parental counterparts, 
a 2-D invasion assay was carried out using the BD 
Falcon™ BioCoat tumour invasion systems (BD Falcon) 
with fluoroBlock™ 96 well insert plate according to 
manufacturers guidelines. This was also compared 
with migration of cells through uncoated BD Falcon™ 
FluoroBlok™ 96 well insert plates. The assay used had 
following steps Rehydration by filling 75 μL of warm 
media and allowed to hehydrated it for 2 hrs at 37˚C at 
5% v/v CO2. Pre-staining the cells by incubating with 
10 μM Cell Trace™ CFSE red dye (Molecular Probes®) 
for 45 min. After incubation the cells were centrifuged 
and re-suspended in serum free media. The cell 
suspension was also added to the apical chambers BD 
falcon fluoroBlock™ 96 well migration plate insert. The 
bottom of the chambers was filled with growth media 
containing 5% v/v FBS. For Doxorubicin resistant cells, 
the apical as well as the bottom chambers were treated 
with 250 ng/mL of Doxorubicin. After incubating the 
plates for 24 hrs at 37°C and 5% CO2 the membranes 
were removed from the inserts and mounted on slides. 
The fluorescence of invaded cells was then read at a 
wavelength of 494/517 nm (Ex/ Em). The number of 
cells invaded from the tumour invasion plate together 
with percentage invasion (see below for equation) was 
analysed using Image J software.
= ×Invasion Number of cells invaded
Number of cellsmigrated
% 100
Cultrex® 96 well 3-D spheroid Basement 
Membrane Extract (BME) cell invasion assay
It should be noted that monolayer cell invasion 
systems are commonly used to evaluate invasion of single 
cells. Therefore, this method is not sufficient to study the 
invasion potential of a spheroid. Although the spheroids 
were artificially separated into single cells to suit the 2-D 
invasion assay, it is not entirely appropriate to compare the 
invasive behaviour of untreated and doxorubicin-treated 
spheroids a further experiment 3-D invasion assay was 
carried out. The assay was carried out according to the 
manufacturer’s guidelines (Cultrex® 3-D spheroid cell 
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invasion assay Amsbio). The plate was then placed under 
a confocal microscope for imaging at 4 hrs intervals for 
48 h. Image J software was used to analyse all confocal 
images, to measure changes in the invasion area at 12, 24 
and 48 h.
Statistical analyses
All data are presented as means ± SD. Statistical 
significance was determined using a one-way ANOVA 
followed by Tukey’s and two-way ANOVA followed by 
Sidak’s test for multiple comparisons and t tests p < 0.05 
was considered statistically significant. (GraphPad Prism, 
version 6, California, USA).
Mass spectrometry analysis
Cell lysates containing 50 μg protein were reduced 
and alkylated (1 μL 0.5 M DTT, 56°C for 20 min; 2.7 
μL 0.55 M iodoacetamide, room temperature 15 min in 
the dark), evaporated to dryness in a vacuum concentrator 
(Eppendorf, UK) and resuspended in 100 μL 50 mM tri-
ethyl ammonium bicarbonate (TEAB). Trypsin (2 μg 
in 2 μL of 1 mM HCl), was added in and incubated in 
a thermomixer overnight at 37°C. Samples were then 
again evaporated to dryness and resuspended in 5% (v/v) 
acetonitrile/0.1% (v/v) formic acid (20 μL) and transferred 
to a HPLC vial for MS analysis. For IDA (Information 
Dependent Analysis) to generate a spectral library, 8 μL of 
pooled sample in triplicate were injected by autosampler 
(Eksigent nanoLC 425 LC system) in microflow at 5 μL/
min directly onto a YMC Triart-C18 column (15 cm, 3 μm, 
300 μm i.d.) using gradient elution (2-40% Mobile phase 
B, followed by wash at 80% B and re-equilibration) over 
87 min. For SWATH/DIA (Data Independent Analysis), 
3 μL was injected on the same gradient elution profile 
over 57 min. Mobile phases consisted of A: 0.1% formic 
acid; B: acetonitrile containing 0.1% (v/v) formic acid. 
IDA analysis was carried out in positive ion mode with a 
250 ms survery scan, m/z range 400-1250; Top 30 peaks 
selected for fragmentation, accumulation time 50 ms per 
experiment, cycle time 1.8 s. SWATH analysis used 100 
variable windows, 25 ms per window, 100-1500 m/z using 
the SCIEX Duospray source with a 50 μm electrode at 
5500v. Spectral libraries were constructed from three IDA 
runs of pooled samples spiked with HRM-kit retention 
time peptides (iRT, Biognosys AG, Switzerland), 
searched using ProteinPilot 5.0 (SCIEX, UK) against the 
Swissprot human database (Jan 2016). The library was 
aligned against the iRT peptides and the SWATH data 
extracted against this library using SCIEX OneOmics 
(SWATH Proteomics Cloud Toolkit) with the parameters 
6 peptides per proteins, 6 transitions per peptide, XIC 
width 75ppm, 5 min extraction window. Analysis of 4 
biological replicates per group was carried out in Protein 
Expression Workflow within OneOmics to identify 
significantly differentially expressed proteins, excluding 
proteins with only single peptides.
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